News | Myriad Genetics

New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight® Psychotropic Test

Products

Myriad Genetics to Release Fourth-Quarter 2021 Financial Results on February 24, 2022

Corporate

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

Corporate

Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care Conference

Corporate

Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service

Corporate

New Year’s Resolutions: Americans Say Body & Mind Equally Important in Theory but Not in Practice, According to GeneSight® Mental Health Monitor Nationwide Survey

Products

Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer

Corporate

The New Generation Gap: Nationwide Survey Finds Different Perspectives on Anxiety Between Parents, Young Adults

Products

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Value of Genetic Testing in Breast Cancer Risk Assessment and Treatment

Pipeline

Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans

Financial

Myriad Genetics to Release Third Quarter Financial Results on November 2, 2021

Financial

Myriad Genetics Names Pamela Wong as Chief Legal Officer

Corporate

Americans’ anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won’t seek treatment according to the GeneSight® Mental Health Monitor nationwide survey

Products

Myriad Genetics Completes Sale of Myriad Autoimmune’s Vectra Testing Business to LabCorp

Corporate

Only 8% of people remain hopeful after depression medication fails them, according to GeneSight® Mental Health Monitor nationwide survey

Products